Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
|
28067908 |
2017 |
Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
Distribution of the ERAP2 SNPs rs2549782 and rs2248374 in patients with AS and in patients with Crohn's disease was assessed.
|
28029742 |
2017 |
Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.
|
26974007 |
2016 |
Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
|
26192919 |
2015 |
Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.
|
26301688 |
2015 |
Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
A functional polymorphism in the gene (rs30187, rs30187" genes_norm="51752">Arg528Lys) associates with susceptibility to ankylosying spondylitis (AS), whereas a SNP in the interacting ERAP2 gene increases susceptibility to another inflammatory autoimmune disorder, Crohn's disease (CD).
|
22253828 |
2012 |
Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.
|
21102463 |
2010 |
Crohn Disease
|
0.420 |
Biomarker
|
disease |
CTD_human |
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.
|
21102463 |
2010 |
Crohn Disease
|
0.420 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.
|
21102463 |
2010 |
Crohn's disease of large bowel
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.
|
21102463 |
2010 |
Crohn's disease of the ileum
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.
|
21102463 |
2010 |
Regional enteritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.
|
21102463 |
2010 |
IIeocolitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.
|
21102463 |
2010 |
Ankylosing spondylitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Results showed that the haplotype H4, containing ERAP1 SNPs associated with high enzymatic activity, together with the presence of ERAP2 expression, significantly increased the risk of AS (OR = 1.97, 95% CI = 1.21-3.21, p<sub>corr</sub> = 0.048).
|
30794838 |
2019 |
Ankylosing spondylitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Several large-scale genomic studies have identified association of members of this family of enzymes, most notably ERAP1 and ERAP2, with immune-mediated diseases including ankylosing spondylitis, psoriasis and birdshot chorioretinopathy.
|
30419264 |
2019 |
Ankylosing spondylitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Because most of the non-B*27 MHC-I molecules associated with AS risk bind a relatively high percentage of peptides with N-terminal basic residues, we hypothesize that the non-epistatic association of ERAP2 with AS might be related to the processing of peptides with these residues, thus affecting the peptidomes of AS-associated MHC-I molecules.
|
31530632 |
2019 |
Ankylosing spondylitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In accordance with studies demonstrating that polymorphisms that increase aminopeptidase activity predispose to immune disease, the increased risk also attributed to increased expression of ERAP1 and ERAP2 supports the notion of using aminopeptidase inhibition to treat AS and other ERAP-associated conditions.
|
29108111 |
2018 |
Ankylosing spondylitis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
ERAP1/ERAP2 and RUNX3 polymorphisms are not associated with ankylosing spondylitis susceptibility in Chinese Han.
|
29480940 |
2018 |
Ankylosing spondylitis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
GWAS have also shown the potential associations between ERAP single nucleotide polymorphisms (SNP) loci and susceptibility to several autoimmune diseases, and ERAP1 and ERAP2 polymorphisms are related to HLA class I-associated diseases, including ankylosing spondylitis and Behçet's disease.
|
28651467 |
2017 |
Ankylosing spondylitis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Distribution of the ERAP2 SNPs rs2549782 and rs2248374 in patients with AS and in patients with Crohn's disease was assessed.
|
28029742 |
2017 |
Ankylosing spondylitis
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Both highly active ERAP1 variants and ERAP2 expression favor AS, whereas loss-of-function ERAP1 and loss-of-expression ERAP2 variants are protective.
|
28063628 |
2017 |
Ankylosing spondylitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
These data support the notion of a peptide-mediated mechanism as the basis for the association of ERAP-2 with ankylosing spondylitis.
|
27110896 |
2016 |
Ankylosing spondylitis
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.
|
26974007 |
2016 |
Ankylosing spondylitis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
It was found that single nucleotide polymorphisms (SNPs) of endoplasmic reticulum aminopeptidase (ERAP1 and ERAP2) genes influence the risk of ankylosing spondylitis, the most common form of SpA and the risk of psoriasis.
|
28083616 |
2016 |
Ankylosing spondylitis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Large differences were not seen in HLA-B27 expression or cytokine levels between subjects with and without ERAP2 in AS cases and controls.
|
26088389 |
2015 |